Dermatologic Therapy最新文献

{"title":"Efficacy of Standard-Dose Omalizumab Against Chronic Urticaria: A Real-World Study","authors":"Zijing Xiao,&nbsp;Duoqin Wang,&nbsp;Yanyun Shen,&nbsp;Yixin Shao,&nbsp;Lisi Peng,&nbsp;Taiyu Jin,&nbsp;Yiqi Zhu,&nbsp;Hui Tang","doi":"10.1155/dth/8754260","DOIUrl":"https://doi.org/10.1155/dth/8754260","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Omalizumab has been recommended for the treatment of CU. Meanwhile, real-world data are available on the efficacy and safety of omalizumab in patients with CSU, but there is a relative paucity of data on the use of the drug in the treatment of CIndU and CSU combined with CIndU.</p>\u0000 <p><b>Objective:</b> To evaluate the efficacy and safety of omalizumab in Chinese patients with CSU, CholU, SDerm, or both, who had an inadequate response to H1-antihistamine treatment.</p>\u0000 <p><b>Methods:</b> This was an observational, retrospective chart review of patients with CU initiating omalizumab treatment.</p>\u0000 <p><b>Results:</b> In total, 78.4% (<i>n</i> = 80/102) of patients showed a response to omalizumab at the end of the study period, and 36.3% (<i>n</i> = 37/102) showed a complete response. Among patients with different subtypes, 84.8% (<i>n</i> = 38/45) of CSU, 37.5% (<i>n</i> = 3/8) of CholU, 50% (<i>n</i> = 1/2) of SDerm and 80.9% (<i>n</i> = 38/47) of CSU + SDerm comorbidity subgroup patients showed a response. The mean of tIgE levels of responders were significantly higher than nonresponders (649.48 ± 814.69 vs. 264.27 ± 262.49 ng/mL, <i>p</i> = 0.004). Patients with isolated CSU exhibited significantly lower relapse rates compared to the CSU + SDerm comorbidity subgroup (42.9% vs. 57.1%, <i>p</i> = 0.042). In total, 12 patients reinitiated omalizumab treatment after a relapse and all of them showed an early response. The mean response time was 1.33 ± 0.65 months. The response mode was similar with their first treatment.</p>\u0000 <p><b>Conclusion:</b> Omalizumab is effective in difficult-to-treat patients with CSU and CSU + SDerm comorbidity subgroup, but the response rates in patients with isolated CholU or SDerm are unsatisfactory. The mean of tIgE levels of responders were significantly higher than nonresponders at baseline. Patients in the CSU + SDerm comorbidity subgroup demonstrate an elevated risk of relapse. These findings support omalizumab’s role in refractory CSU and comorbid CSU + SDerm, but highlight unmet needs in isolated CIndU subtypes.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8754260","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Efficacy and Safety of Upadacitinib Combined With a 308 nm Excimer Laser in the Treatment of Refractory Vitiligo Complicated With Atopic Dermatitis","authors":"Fangfei Zhou,&nbsp;Weiye Li,&nbsp;Yuhang Liu,&nbsp;Qiuyue Jin,&nbsp;Wenzhao Han,&nbsp;Jiaqi Li,&nbsp;Xiang Liu","doi":"10.1155/dth/9949035","DOIUrl":"https://doi.org/10.1155/dth/9949035","url":null,"abstract":"<div>\u0000 <p>Vitiligo is autoimmune-induced skin depigmentation. Phototherapy is commonly used as the basic treatment for vitiligo; however, its curative effect is limited in some cases of refractory vitiligo. This study aimed to evaluate the clinical efficacy and safety of upadacitinib combined with a 308 nm excimer laser (308 nm EL) for treating refractory vitiligo with moderate-to-severe atopic dermatitis (AD). We analyzed the treatment of 19 Chinese patients with skin diseases and found that sex, disease duration, and skin type did not affect repigmentation, whereas age was negatively correlated with repigmentation. After 4 months of therapy, the overall remission degree of the vitiligo area severity index (VASI) score reached 55.00%, and the last 2 months were better than the first 2 months. The curative effect of vitiligo on the face and neck was better, with an improvement of &gt; 70.00%, followed by the torso, arms, and legs. The VASI scores of the hands and feet were the worst, especially the feet which scored only 28.00%. The average improvement in the SCORing of AD (SCORAD) and dermatology life quality index (DLQI) scores was 41.89% and 49.12%, respectively. No serious adverse events were observed. Overall, upadacitinib combined with 308-nm EL showed promising clinical value for the treatment of refractory vitiligo.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9949035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144291892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Risk Factors for Poor Efficacy of Adalimumab Treatment in Patients With Crohn’s Disease: Insights From Machine Learning Models","authors":"Xiaojun Li,&nbsp;Maomao Tang,&nbsp;Jie Zhang,&nbsp;Yongjun Wang,&nbsp;Chunlian Wang,&nbsp;Chunhui Ouyang","doi":"10.1155/dth/1996661","DOIUrl":"https://doi.org/10.1155/dth/1996661","url":null,"abstract":"<div>\u0000 <p><b>Aim:</b> Adalimumab (ADA) is an effective treatment for Crohn’s disease (CD); however, some patients still experience adverse reactions and nonresponse. This study aimed to explore the risk factors associated with ADA poor efficacy through machine learning algorithms, which provide promising guidance for the management of ADA in clinical practice.</p>\u0000 <p><b>Methods:</b> This single-center investigation included 114 CD patients treated with ADA in the Department of Gastroenterology from January 2020 to January 2023. Risk factors associated with each poor efficacy event were explored using logistic regression and machine learning algorithms. Shapley additive explanations (SHAP) and partial dependence plot methods were used to analyze the risk factors of each event.</p>\u0000 <p><b>Results:</b> The results showed 8 of these patients experienced primary non-response (PNR), 35 patients developed secondary loss of response (LOR), and 27.2% (31/114) of patients experienced at least one adverse events (AEs). After comparing the fit of the models established by 10 algorithms, the risk factors associated with PNR, LOR, and AEs were analyzed using the logistic regression algorithm, KNN algorithm, and Extra Tree algorithm, respectively. The most important variables related to the PNR, LOR, and AEs events were the history of corticosteroid use, baseline CDAI, and uric acid, respectively.</p>\u0000 <p><b>Conclusions:</b> This study confirmed the efficacy of ADA for clinical practice in the Chinese CD population, and that patients with a history of corticosteroid use, high levels of disease activity, and high inflammatory state before ADA treatment were associated with increased risks of poor efficacy.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1996661","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144273444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiences of Cutaneous Immune-Related Adverse Events: A Qualitative Study in Patients With Cancer Receiving Immune Checkpoint Inhibitors","authors":"Zhihui Yang,&nbsp;Ruiqi Lu,&nbsp;Xingwen Li,&nbsp;Suting Liu,&nbsp;Yuanyuan Luo,&nbsp;Ziqi Wang,&nbsp;Yang Zhao,&nbsp;Lili Zhang","doi":"10.1155/dth/7119579","DOIUrl":"https://doi.org/10.1155/dth/7119579","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Cutaneous immune-related adverse events (cirAEs) represent a prevalent manifestation of adverse reactions linked to immune checkpoint inhibitors (ICIs) therapy, substantially affecting patients’ quality of life.</p>\u0000 <p><b>Objective:</b> To describe the symptomatic experience of cirAEs in patients with cancer receiving ICIs.</p>\u0000 <p><b>Design:</b> Qualitative interviews on experiences were conducted from the perspective of patients with cancer.</p>\u0000 <p><b>Methods:</b> A purposive sample of 18 patients with cirAEs participated in this semistructured interview. Transcripts were entered into Nvivo 11.0. Qualitative content analysis was used to analyze the data for significant statements and phrases, which were organized into themes and subthemes.</p>\u0000 <p><b>Results:</b> Three main themes were identified in the data: (i) multiple emotions coexist, affecting the quality of life; (ii) insufficient coping capacity for cirAEs management; and (iii) exploring needs and expectations for management with cirAEs.</p>\u0000 <p><b>Conclusions:</b> The results of this study enable healthcare providers to better understand and empathize with the patient’s experience, to truly practice the essence of patient-centered care, and to provide a basis for the development of standardized symptom management programs in the future.</p>\u0000 <p><b>Implications for Clinical Practice:</b> To strengthen patient education by clarifying knowledge of cirAEs and providing evidence-based coping strategies, formulate personalized management plans supported by multidisciplinary collaboration when necessary, establish standardized symptom management protocols incorporating regular monitoring and dynamic strategy adjustments, and promote patient participation in decision-making while building support networks to enhance self-efficacy, thereby laying the foundation for future standardized management protocols through patient-centered integrated management approaches.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7119579","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pruritus and Its Association With Cancer and Mortality in Dermatomyositis and Polymyositis: A Nationwide Cohort Study in Taiwan From 2005 to 2022","authors":"Der-Jr Huang,&nbsp;Yu-Hsuan Joni Shao,&nbsp;Yi-Hsien Shih,&nbsp;Woan-Ruoh Lee,&nbsp;Ling-Ya Huang,&nbsp;Yu-Min Kuo,&nbsp;Quoc Thao Trang Pham,&nbsp;Hao-Jui Weng","doi":"10.1155/dth/9963667","DOIUrl":"https://doi.org/10.1155/dth/9963667","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Pruritus is the most common initial symptom reported by patients with dermatomyositis (DM) and polymyositis (PM). However, there is limited data regarding the impact of pruritus on cancer and mortality in patients with DM and PM. In this study, we aimed to investigate how pruritus is associated with cancer and mortality in patients with DM and PM.</p>\u0000 <p><b>Methods:</b> This nationwide, population-based retrospective cohort study included adult DM and PM patients from Taiwan’s National Health Insurance Research Database between 2005 and 2022. Sex- and age-matched pruritic patients, identified by over 6 weeks of antipruritic medication use, and nonpruritic patients were analyzed. The primary outcome was cancer occurrence or all-cause mortality. The association between pruritus and these outcomes was estimated using Cox proportional hazards models.</p>\u0000 <p><b>Results:</b> Among 919 matched pairs of pruritic and nonpruritic patients, cancer was observed in 19.96% in the long-term pruritic group (LPG), 14.63% in the short-term pruritic group (SPG), and 10.34% in the non-pruritic group (NPG) (<i>p</i> &lt; 0.0001). All-cause mortality was documented as 30.37% in the LPG, 29.69% in the SPG, and 37.76% in the NPG (<i>p</i> &lt; 0.0001). After adjusting for sex, age, and other comorbidities, pruritus was associated with an increased risk of cancer (hazard ratio (HR) 1.708, 95% confidence interval (CI) 1.229–2.374) and a lower risk of all-cause mortality (HR 0.483, 95% CI 0.409–0.569).</p>\u0000 <p><b>Conclusion:</b> This population-based study revealed that pruritus appeared to be associated with increased risks of cancer and decreased all-cause mortality. Thus, pruritus may serve as a pragmatic factor for risk stratification and tailored treatment strategies in DM and PM. Cancer screening, particularly for nasopharyngeal and breast cancers in East Asian populations, is recommended for patients with DM or PM, especially those presenting with pruritus. Meanwhile, patients without pruritus may require vigilant management for potentially life-threatening complications and comorbidities.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9963667","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144244901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phospholipid Detection From Surgical Smoke Distinguishes Basal Cell Carcinoma: A Proof-of-Principle Study","authors":"Anni Salminen,&nbsp;Patrik Sioris,&nbsp;Juha Jernman,&nbsp;Nele Veide,&nbsp;Anton Kontunen,&nbsp;Meri Mäkelä,&nbsp;Markus Karjalainen,&nbsp;Minna Kelloniemi,&nbsp;Niku Oksala,&nbsp;Antti Roine","doi":"10.1155/dth/6179799","DOIUrl":"https://doi.org/10.1155/dth/6179799","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Basal cell carcinoma (BCC) is a nonmelanocytic skin cancer and the most common malignancy in Caucasians. Diagnostics and treatment of BCC cause significant health-related stress for many patients and costs for public health care systems. Differential mobility spectrometry (DMS) is a sensitive method for detection of gaseous molecules. The DMS-derived automatic tissue analysis system (ATAS) utilises diathermy-generated surgical smoke to distinguish cancerous tissue from normal tissue based on lipid profiling between the tissues.</p>\u0000 <p><b>Objectives:</b> The aim of this study was to create a surrogate porcine model to test the feasibility of the ATAS in lipid detection of skin. Another objective was to determine whether BCC of human skin could be identified from healthy skin using lipid profiling.</p>\u0000 <p><b>Methods:</b> Porcine ear skin was used to establish a three-group porcine model for lipid profile detection. Lecithin was chosen as a marker to demonstrate elevated phospholipid levels in one of the groups. We also recruited five BCC patients to collect BCC tumour biopsies and healthy skin biopsies to test the model in human samples. In both models, all samples were processed with the ATAS to test the accuracy of lipid profiling and resolution between the groups.</p>\u0000 <p><b>Results:</b> In the porcine model<span>,</span> the classification accuracy was 74.5% for three groups (unprocessed porcine skin, fine-grained porcine skin, and lecithin-marked fine-grained porcine skin) and 91.8% for two groups (unprocessed porcine skin and fine-grained porcine skin combined into one group in comparison to lecithin-marked fine-grained porcine skin). The support vector machine (SVM) classifier model trained on porcine surrogate samples was then used to analyse a small number of human BCC and healthy skin samples with 95% accuracy.</p>\u0000 <p><b>Conclusion:</b> DMS-based differentiation of porcine skin samples based on surgical smoke is possible. This study is a step towards a method to distinguish human BCC from healthy skin from surgical smoke by the ATAS. The presented skin identification of DMS analysis of surgical smoke opens the possibility to research the method in a larger sample number of human BCC and healthy skin samples as well as develop the method and ATAS towards a clinical tool for margin assessment.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6179799","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144244532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonablative Er:YAG Laser Treatment of Androgenetic Alopecia: A Clinical Observation","authors":"Qiongyu Zhang,&nbsp;Enpin Yang,&nbsp;Lin Cong,&nbsp;Xuesong Yang,&nbsp;Jianzhou Ye,&nbsp;Wenbin Zhao,&nbsp;Guilan Hu,&nbsp;Iva Talaber","doi":"10.1155/dth/2419414","DOIUrl":"https://doi.org/10.1155/dth/2419414","url":null,"abstract":"<div>\u0000 <p><b>Background and Aim:</b> Androgenetic alopecia (AGA) is a common hair disorder with a low cure rate. Nonablative Er:YAG laser therapy is a novel treatment modality for AGA, representing an alternative to pharmacological and surgical treatment. To date, several small scale studies employing this laser treatment have demonstrated good results but the evidence is still limited. The aim of this study was to evaluate effectiveness and safety of a nonablative 2940 nm Er:YAG laser for treating AGA in female and male patients with both early and advanced stages of AGA.</p>\u0000 <p><b>Methods:</b> Patients (22 male and 10 female) with active AGA were treated with 2940 nm nonablative Er:YAG laser (SMOOTH™ mode, 7 mm spot size, 7.5–10 J/cm², and frequency 2.5 Hz). Efficacy of treatment was evaluated clinically on a scale of 0–10 and with blind evaluation of hair appearance as seen in global photographs. Global photographs were taken before treatment and at 1-month follow-up and evaluated on a 5-point scale. Patient satisfaction was evaluated with a questionnaire on a scale from 0 to 3 and pain during treatment was evaluated with a pain scale from 0 to 10.</p>\u0000 <p><b>Results:</b> Median clinical improvement was 6 (1–9), median satisfaction score was 3 (0–3), and median pain degree was 3 (0–10). According to blind evaluation, hair appearance at the 1-month FU was better in 63% and much better in 9% of the patients compared with the baseline. No adverse reactions were reported.</p>\u0000 <p><b>Conclusions:</b> The results of this study corroborate the effectiveness of treatment with nonablative Er:YAG laser therapy for AGA. Six biweekly sessions resulted in general patient satisfaction and visible improvement in hair appearance.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2419414","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Night Peeling With Azelaic Acid on Mature Facial Skin Parameters After 28 Days of Use: Preliminary Report","authors":"M. Drozdova-Statkevičienė,&nbsp;R. Rauluševičienė","doi":"10.1155/dth/9941546","DOIUrl":"https://doi.org/10.1155/dth/9941546","url":null,"abstract":"<div>\u0000 <p>The aim of this study was to determine the effect of night peeling with azelaic acid (AA) on the parameters of mature facial skin after 28 days of use. The sample consisted of 28 participants (six participants did not complete the study for reasons unrelated to cosmetic intolerance), aged 40–68 years old, including both men and women, with dry and/or normal skin types, closed comedones, and visible signs of aging. The study lasted 28 days, during which all participants were evaluated before and after the treatment with the night peeling containing AA. The results showed that not all parameters changed significantly. Significant changes was observed in the skin moisture level (increased by 4%), skin elasticity (improved by 11%), and wrinkle length (reduced by 4%). In addition, it reduced wrinkle count by an average of 15%, wrinkle volume by an average of 8%, and wrinkle area by an average of 5%. These findings indicate a successful response to the night peeling treatment with AA. However, the study was relatively small in size and could be extended to include more subjects and investigate the use of the product over a longer period of time.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9941546","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Real-World Safety Profile of Secukinumab Assessed Through a 9-Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study","authors":"Elena Ippoliti,&nbsp;Gennaro Marco Falco,&nbsp;Tiago Torres,&nbsp;Eleonora De Luca,&nbsp;Clara De Simone,&nbsp;Giacomo Caldarola,&nbsp;Augusta Ortolan,&nbsp;Arianna Guaita,&nbsp;Andrea Chiricozzi,&nbsp;Giusy Peluso,&nbsp;Ketty Peris,&nbsp;Maria Antonietta D’Agostino","doi":"10.1155/dth/9618241","DOIUrl":"https://doi.org/10.1155/dth/9618241","url":null,"abstract":"<div>\u0000 <p>Secukinumab is a biologic agent known for its durable efficacy in chronic plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Monitoring the safety of secukinumab is a priority to ensure its long-term usage. We aimed to provide an extended safety assessment of secukinumab treatment in a real-world setting. This bicentric observational study enrolled 332 patients with PsO, PsA and AS who received subcutaneous injections of secukinumab for up to 9 years. Adverse events (AEs) were reported annually as exposure-adjusted incidence rates (EAIRs) per 100 patient-years (pt-y). The total secukinumab exposure was 1129 pt-y. The retention rate was 73%, with 16 (4.8%) of patients discontinuing due to AEs. Despite most AEs being reported within the first 2 years, their incidence was low and decreased over time. The EAIR of any AEs was the highest in the initial 6 months (32.72/100 pt-y), followed by year 1 (7.62/100 pt-y), and year 2 of treatment (3.01/100 pt-y). Common AEs included respiratory and urinary tract infections, candidiasis, and diarrhoea. Secukinumab showed sustained safety over an extended 9-year treatment period, supporting its use for the long-term management of these immune-inflammatory disorders.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9618241","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144125991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Controlled Study of the Efficacy of a Topical Antifungal, Antimicrobial, Anti-Inflammatory, and Antiseborrheic Cream in Treating Mild to Moderate Facial Seborrheic Dermatitis","authors":"Kridipop Charoenchaipiyakul,&nbsp;Patcharapong Rujirawan,&nbsp;Nopadon Noppakun,&nbsp;Yuda Chongpison,&nbsp;Chanat Kumtornrut","doi":"10.1155/dth/8887280","DOIUrl":"https://doi.org/10.1155/dth/8887280","url":null,"abstract":"<div>\u0000 <p>Seborrheic dermatitis (SD) presents treatment challenges due to its complex pathogenesis. A nonsteroidal cream (NSC) with antifungal, antimicrobial, anti-inflammatory, and antiseborrheic properties containing piloctone olamine, biosaccharide gum-2, stearyl glycyrrhetinate, and zinc PCA has shown promise in previous studies with the design that lacked control groups and demographic diversity. To validate its efficacy, this randomized, assessor-blinded, controlled trial included 50 Thai subjects with mild-to-moderate facial SD. Participants were randomized 1:1 to apply either NSC or a hydrophilic cream (control) twice daily for 8 weeks. Assessments at week (W) 0, 4, 8, and 12 (4 weeks posttreatment) included severity scores (mSDASI), Investigator Global Assessment (IGA), pruritus, and skin biophysics (erythema index, hydration, TEWL, and sebum levels). The use of triamcinolone acetonide 0.02% cream as rescue medication was recorded. Both NSC (<i>n</i> = 25) and control (<i>n</i> = 25) groups showed clinical improvement from W4, peaking at W8 and continuing to W12. The NSC group’s mSDASI significantly differed from controls at W8 (<i>p</i> = 0.043). The proportion of subjects achieving successful IGA (&gt; 80% improvement) was significantly higher in the NSC group at W8 (44% vs. 16%, <i>p</i> = 0.048). NSC also significantly reduced erythema index at all visits and sebum levels at W4, with lower trends toward pruritus and rescue medication use during treatment. No adverse effects were reported. Overall, NSC demonstrated positive therapeutic effects for mild to moderate facial SD in Southeast Asians, highlighting its potential as a treatment option.</p>\u0000 <p><b>Trail Registration:</b> Thai Clinical Trials Registry: TCTR20230811003</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8887280","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144074322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}